




for Pharmaceutical Pricing and Reimbursement Policies

WHO Collaborating Centre

DENMARK

Recent and planned developments in pharmaceutical policies 2016 Special topic: Pricing and reimbursement policies for biosimilars



education material for doctors, nurses, pharmacists, and patients.

Т

0

Ρ

С

And when the documentation from the EMA approval was available, there have been discussions with the doctors, and based upon these discussions, the doctors decided when to switch patients.

For both products, there has been a statement that unless the patients have problems, it will be possible to switch the patient from the original products to the biosimilar products.

The introduction of infliximab went much quicker than expected. In month 2, infliximab had a MS of 90%. The introduction of Benepali will begin 1st May, 2016.